

Growth of Extracranial Radiosurgery Highlighted at Annual CyberKnife® Users' Meeting

Meeting features CyberKnife® applications for lesions of the spine, pancreas, lung, and pelvis

Sunnyvale, California, December 12, 2003 – Accuray Incorporated, the world leader in full-body image-guided radiosurgery, announced today that the Third Annual CyberKnife® Users' Meeting was held November 13-15 at the Silverado Resort in Napa Valley, California. Extracranial radiosurgery using the CyberKnife® Stereotactic Radiosurgery System was the highlighted topic at the meeting, which was co-hosted by Accuray and the CyberKnife® Society.

The Users' Meeting featured clinical presentations by users from around the world and provided opportunity for networking and education on new technological and clinical advances with the CyberKnife® System. Over 110 participants attended, representing surgeons, radiation oncologists, physicists, and other affiliated medical personnel from 20 sites throughout the world.

John Adler, MD, President of the CyberKnife® Society, commented, "A wealth of information was shared at this meeting to provide users insight on the novel clinical applications now being pursued with the CyberKnife® technology. In particular, data from studies using staged or hypofractionated radiosurgery presented at the meeting suggests improved clinical outcomes for patients with acoustic neuroma and peri-optic lesions. Furthermore, preliminary studies suggest that CyberKnife® radiosurgery may have a promising role treating locally advanced pancreatic cancer and peri-aortic lymph node metastases from cervical and colorectal cancer. This meeting has been an excellent forum for users to meet in person, share clinical experiences, and foster a sense of excitement throughout our evolving community – a role that the CyberKnife® Society continues to actively promote for users through its website."

At the meeting, Accuray also announced its commitment to standardized protocol development through the company's plans to sponsor two multi-center outcome studies. One study will evaluate dynamic radiosurgery of lung tumors using CyberKnife® with Synchrony, Accuray's product that tracks and delivers precision radiosurgery to targets which move throughout respiration. The other study will focus on staged CyberKnife® radiosurgery of spinal lesions. Both studies are currently undergoing design and development.

Thierry Thauere, Accuray's Senior Vice President of Sales and Marketing, commented, "The growing trend towards extracranial applications was very evident at this meeting. Of our 24 clinical presentations by users, 17 covered extracranial topics. Usage analysis at our sites has shown that the percentage of extracranial treatments has been steadily increasing annually and already exceeds 40% at some sites. Based on this trend, we expect that by the next Users' Meeting, 50% of all CyberKnife® cases being performed each year will be extracranial. This trend, which is completely redefining the radiosurgery market, is made possible by our advanced image-guidance technology that is the only system in the world capable of correcting for patient

movement in real-time, enabling the CyberKnife to achieve sub-millimeter total clinical accuracy anywhere in the body.”

Attendee James Schwade, MD, Director of the CyberKnife® Center of Miami, Florida, commented, “The Users’ Meeting has been a valuable means of staying abreast of new applications, technological improvements, and related topics of interest such as reimbursement issues and customer service. Our new CyberKnife® Center opens in Miami in two weeks and the knowledge base represented at the Users’ Meeting will be a great resource for our successful launch.”

About the CyberKnife® System:

The CyberKnife® Stereotactic Radiosurgery System is a non-invasive, 100% frameless image-guided radiosurgery system that can ablate tumors and other lesions anywhere in the body without open surgery. The CyberKnife® treats in single or staged (typically 2-5) sessions, and monitors internal reference points in the anatomy (skeletal landmarks or small implanted markers) to correct in real-time for patient movement during actual treatment. It delivers multiple beams of precisely directed radiation that converge upon the tumor while minimizing injury to surrounding healthy tissue.

The CyberKnife® is the only system in the world that integrates image-guidance and robotic delivery of radiation to deliver proven sub-millimeter total clinical accuracy with T⁴ or Tight to the Tumor conformality. The sub-millimeter accuracy allows higher doses of radiation to be used, providing potential for greater tumor-killing efficacy and greater likelihood of cure.

The unique CyberKnife® technology, which was developed in cooperation with Stanford University, was cleared by the FDA in August 2001 and received CE approval in September 2002 to provide radiosurgery for lesions anywhere in the body when radiation treatment is indicated. To date, the CyberKnife® System has been used to treat more than 6,500 patients worldwide.

About Accuray:

Accuray is a privately held corporation whose primary focus is to revolutionize the treatment of solid cancers anywhere in the body by the precise delivery of high doses of radiation using the CyberKnife® Radiosurgery System. Through the development and promotion of the CyberKnife® System and participation in ongoing clinical research at prominent academic hospitals, Accuray will help make stereotactic radiosurgery a viable and accessible option for patients all over the world. Located in Sunnyvale, California, the heart of the Silicon Valley, the company designs, manufactures, and distributes the CyberKnife® Radiosurgery System worldwide.

For more information on Accuray or the CyberKnife® please contact:

Lauren Selmeier, Vice President of Marketing
Accuray Incorporated, 1310 Chesapeake Terrace, Sunnyvale, CA 94089; Tel: (888) 522-3740; Fax: (408) 716-4620
Email: info@accuray.com; or visit our website at <http://www accuray.com>.